The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The US Food and Drug Administration (FDA) has approved tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide
Early recovery of specific T-cell counts and natural killer (NK) cell counts after CD19 chimeric antigen receptor (CAR)-T therapy can be used as
A small study found that among pregnancies in which the mother was exposed to ponatinib, cases of Hirschsprung’s disease (HD) occurred. Paternal exposure
A study compared second-line treatment options for essential thrombocythemia (ET) and found that ropeginterferon alfa-2b “outperformed” anagrelide in both efficacy and safety outcomes.
Follow-up results from the BELLWAVE-003 study assessing nemtabrutinib in patients with hematologic malignancies showed continued antitumor activity and no new safety concerns with
Andrew Kuykendall, MD, SOHO Insider MPN podcast host, and assistant professor in the Department of Malignant Hematology at Moffitt Cancer Center, delivers live
A post-hoc analysis found that the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) produced durable remissions and maintained a favorable benefit-risk profile
Meet Jesus Gonzalez Lugo, MD, an assistant professor of medicine at the University of Kansas and a 2024 SOHO Young Investigator Program (YIP)
Researchers conducted a proof-of-concept study for genetically redirecting T cells, offering a potential immunotherapy target for acute myeloid leukemia (AML) and myelodysplastic syndromes
Patients with newly-diagnosed multiple myeloma (MM) treated with isatuximab plus carfilzomib, lenalidomide, dexamethasone (IsaKRD) in induction, consolidation, and light consolidation phases saw sustained measurable
